Mavoglurant
id:
mavoglurant-248-8542684
title:
Mavoglurant
text:
Mavoglurant (developmental code name AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome and other conditions. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGluR5). Mavoglurant was under development by Novartis and reached phase II and phase III clinical trials. Phase IIb/III dose finding and evaluation trials for fragile X-syndrome were discontinued by the end of 2014. Otherwise, it would have been the first drug to treat the und
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/Mavoglurant
date created:
date modified:
2024-02-12T19:48:31Z
main entity:
{"identifier":"Q6589598","url":"https://www.wikidata.org/entity/Q6589598"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/f/fb/Mavoglurant.svg","width":512,"height":790}
fields total:
13
integrity:
15